Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits
2011

Mucosal Targeting of a Botulinum Vaccine Enhances Antibody Induction in Rabbits

Sample size: 24 publication 10 minutes Evidence: high

Author Information

Author(s): Herman F. Staats, Jeffrey R. Fielhauer, Afton L. Thompson, Alice A. Tripp, Ashley E. Sobel, Massimo Maddaloni, Soman N. Abraham, David W. Pascual

Primary Institution: Duke University Medical Center

Hypothesis

Does the addition of a mucosal targeting ligand enhance the immunogenicity of a botulinum neurotoxin vaccine in rabbits?

Conclusion

The study found that the mucosal targeting ligand Ad2F significantly enhanced the immunogenicity of the botulinum neurotoxin vaccine in rabbits.

Supporting Evidence

  • Hcβtre-Ad2F induced higher serum anti-Hcβtre IgG titers compared to Hcβtre alone.
  • C48/80 provided significant nasal adjuvant activity.
  • Immunization with Hcβtre-Ad2F resulted in superior induction of BoNT/A neutralizing antibodies.

Takeaway

Researchers tested a new vaccine for botulinum toxin in rabbits and found that adding a special ingredient helped the vaccine work better.

Methodology

New Zealand White and Dutch Belted rabbits were nasally immunized with different formulations of the vaccine, and serum samples were analyzed for antibody levels.

Potential Biases

Potential bias in the selection of adjuvants and immunogens used in the study.

Limitations

The study was limited to rabbit models, which may not fully represent human responses.

Participant Demographics

Female New Zealand White and Dutch Belted rabbits were used in the study.

Statistical Information

P-Value

0.0006

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016532

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication